Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Caroline Piatek, MD
Irina Murakhovskaya, MD
Thomas Kipps, MD, PhD
Thomas Kipps, MD, PhD
William Wierda, MD, PhD